Strachan et al. demonstrated that targeting the Csf-1-receptor with a small molecule inhibitor attenuated the turnover rate of TAMs and decreased tumor growth in mouse models of breast and cervical cancer (151). The gene discussed is CSF1R; the disease is cervical cancer.